Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one […]
More Stories
Snowflake (NYSE:SNOW) Price Target Raised to $250.00
Snowflake (NYSE:SNOW – Free Report) had its target price increased by Royal Bank of Canada from $236.00 to $250.00 in...
Defense Stocks To Watch Now – June 2nd
Boeing, GE Aerospace, Citigroup, BigBear.ai, and Lockheed Martin are the five Defense stocks to watch today, according to MarketBeat’s stock...
Promising Fertilizer Stocks To Follow Now – June 2nd
CSX, Union Pacific, Canadian Pacific Kansas City, Norfolk Southern, and Petróleo Brasileiro S.A. – Petrobras are the five Fertilizer stocks...
Wealth Enhancement Advisory Services LLC Has $2.91 Million Stock Holdings in Take-Two Interactive Software, Inc. (NASDAQ:TTWO)
Wealth Enhancement Advisory Services LLC increased its position in shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO – Free Report) by...
Wealth Enhancement Advisory Services LLC Purchases 12,782 Shares of FS KKR Capital Corp. (NYSE:FSK)
Wealth Enhancement Advisory Services LLC boosted its position in FS KKR Capital Corp. (NYSE:FSK – Free Report) by 11.0% in...
Trump Bans New Visas for Foreign Nationals From 12 Countries
By T. J. Muscaro President Donald Trump on June 4 issued a full suspension on new visas for foreign nationals...